Third Child’s The Charm: Will China's New Policy Stimulate Pediatric Market?
Reimbursement, Pricing Hurdles Remain
A newly issued rule to allow couples to have up to three children may be too little, too late to incentivize China's anemic pediatric drug development market, now dominated by traditional medicines.
You may also be interested in...
Confounding earlier speculation, the first CAR-T cell therapy to gain approval in China is from the Fosun-Kite joint venture rather than Juno-WuXi AppTec. But pricing and market competition challenges are just beginning.
In the latest sign that some multinationals are scaling down operations in the world's second-largest pharma market, Mundipharma is reported to be exploring the sale of its business in China, with a large group of bidders including state-owned Sinopharm and local private equity firm Boyu Capital in the running.
Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.